Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 89Zr radiochemistry for positron emission tomography.

Literature DB >> 21711221

89Zr radiochemistry for positron emission tomography.

Gregory W Severin¹, Jonathan W Engle, Todd E Barnhart, R Jerry Nickles.

Abstract

The positron emitting isotope (89)Zr is an ideal radionuclide for use in positron emission tomography (PET) imaging with monoclonal antibodies (mAbs). This article reviews the cyclotron physics of (89)Zr production, and the chemical separation methods for isolating it from yttrium target material. (89)Zr coordination with the bifunctional chelate desferrioxamine B is discussed, along with the common procedures for attaching the chelate to mAbs. The review is intended to detail the procedure for creating (89)Zr labeled mAbs, going from cyclotron to PET.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21711221 PMCID： PMC4568753 DOI： 10.2174/157340611796799186

Source DB: PubMed Journal: Med Chem ISSN： 1573-4064 Impact factor: 2.745

28 in total

Review 1. The promise of immuno-PET in radioimmunotherapy.

Authors: Iris Verel; Gerard W M Visser; Guus A van Dongen
Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057

2. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Authors: Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal: Nat Protoc Date: 2010-03-25 Impact factor: 13.491

3. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Authors: Wouter B Nagengast; Maarten A de Korte; Thijs H Oude Munnink; Hetty Timmer-Bosscha; Wifred F den Dunnen; Harry Hollema; Johan R de Jong; Michael R Jensen; Cornelia Quadt; Carlos Garcia-Echeverria; Guus A M S van Dongen; Marjolijn N Lub-de Hooge; Carolien P Schröder; Elisabeth G E de Vries
Journal: J Nucl Med Date: 2010-04-15 Impact factor: 10.057

4. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

Authors: Lars R Perk; Gerard W M Visser; Maria J W D Vosjan; Marijke Stigter-van Walsum; Bernard M Tijink; C René Leemans; Guus A M S van Dongen
Journal: J Nucl Med Date: 2005-11 Impact factor: 10.057

5. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Authors: Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis
Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057

6. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.

Authors: Hugo J W L Aerts; Ludwig Dubois; Lars Perk; Peter Vermaelen; Guus A M S van Dongen; Bradly G Wouters; Philippe Lambin
Journal: J Nucl Med Date: 2008-12-17 Impact factor: 10.057

7. A facile method for the labeling of proteins with zirconium isotopes.

Authors: W E Meijs; H J Haisma; R Van der Schors; R Wijbrandts; K Van den Oever; R P Klok; H M Pinedo; J D Herscheid
Journal: Nucl Med Biol Date: 1996-05 Impact factor: 2.408

8. Adsorption behaviors of high-valence metal ions on desferrioxamine B immobilization nylon 6,6 chelate fiber under highly acidic conditions.

Authors: Yoshitaka Takagai; Atsushi Takahashi; Hitoshi Yamaguchi; Toshio Kubota; Shukuro Igarashi
Journal: J Colloid Interface Sci Date: 2007-04-17 Impact factor: 8.128

9. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

Authors: Iris Verel; Gerard W M Visser; Ronald Boellaard; Otto C Boerman; Julliette van Eerd; Gordon B Snow; Adriaan A Lammertsma; Guus A M S van Dongen
Journal: J Nucl Med Date: 2003-10 Impact factor: 10.057

10. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Authors: Wouter B Nagengast; Elisabeth G de Vries; Geke A Hospers; Nanno H Mulder; Johan R de Jong; Harry Hollema; Adrienne H Brouwers; Guus A van Dongen; Lars R Perk; Marjolijn N Lub-de Hooge
Journal: J Nucl Med Date: 2007-07-13 Impact factor: 10.057

16 in total

Review 1. Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain.

Authors: Kaihua Chen; Mengchao Cui
Journal: Medchemcomm Date: 2017-05-16 Impact factor: 3.597

Review 2. Positron emission tomography imaging using radiolabeled inorganic nanomaterials.

Authors: Xiaolian Sun; Weibo Cai; Xiaoyuan Chen
Journal: Acc Chem Res Date: 2015-01-30 Impact factor: 22.384

Review 3. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors: Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal: Nucl Med Biol Date: 2012-09-19 Impact factor: 2.408

4. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.

Authors: Brian M Zeglis; Jason S Lewis
Journal: J Vis Exp Date: 2015-02-12 Impact factor: 1.355

5. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Authors: Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis
Journal: Inorg Chem Date: 2013-12-06 Impact factor: 5.165

6. ⁸⁹Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma.

Authors: Raquel Benedetto; Adriana V F Massicano; Bryant K Crenshaw; Renato Oliveira; Rui M Reis; Elaine B Araújo; Suzanne E Lapi
Journal: Cancer Biother Radiopharm Date: 2019-03-13 Impact factor: 3.099

89Zr radiochemistry for positron emission tomography.

Review 1. The promise of immuno-PET in radioimmunotherapy.

2. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

3. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

4. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

5. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

6. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.

7. A facile method for the labeling of proteins with zirconium isotopes.

8. Adsorption behaviors of high-valence metal ions on desferrioxamine B immobilization nylon 6,6 chelate fiber under highly acidic conditions.

9. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

10. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Review 1. Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain.

Review 2. Positron emission tomography imaging using radiolabeled inorganic nanomaterials.

Review 3. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

4. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.

5. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

6. ⁸⁹Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma.

7. Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.

Review 8. Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Review 9. ⁸⁹ Zr-ImmunoPET companion diagnostics and their impact in clinical drug development.

10. Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).

Review 1. The promise of immuno-PET in radioimmunotherapy.

Review 1. Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain.

Review 2. Positron emission tomography imaging using radiolabeled inorganic nanomaterials.

Review 3. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Review 8. Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Review 9. 89 Zr-ImmunoPET companion diagnostics and their impact in clinical drug development.

Review 9. ⁸⁹ Zr-ImmunoPET companion diagnostics and their impact in clinical drug development.